Tranexamic Acid vs Hydroquinone for Melasma: A Complete Comparison

2 hours ago
5 min read

Tranexamic acid and hydroquinone are the two most studied treatments for melasma, and they work on entirely different points of the pathway. Hydroquinone suppresses pigment production inside the melanocyte; tranexamic acid interrupts the upstream signalling that tells the melanocyte to produce pigment in the first place. That mechanistic difference explains why one is a short-course depigmenting agent with a defined stopping point, and the other is increasingly used as a longer maintenance strategy. This guide compares how each works, what the evidence shows, the safety limits that matter in darker skin types, and how Korean clinics typically sequence them.

How Hydroquinone Works

Hydroquinone is a phenolic compound that competitively inhibits tyrosinase, the rate-limiting enzyme converting tyrosine into melanin. With tyrosinase suppressed, existing melanocytes continue to function but produce substantially less pigment. It has been the reference standard for melasma for decades and remains the agent against which new treatments are benchmarked.

It is typically prescribed at 2 to 4 percent, often within a triple-combination formulation that adds a retinoid and a mild corticosteroid. Onset is not immediate: meaningful lightening usually becomes visible after roughly 8 to 12 weeks of consistent use. Crucially, hydroquinone is intended for defined courses rather than indefinite use.

How Tranexamic Acid Works

Tranexamic acid is a lysine analogue originally developed as an antifibrinolytic to reduce bleeding. Its effect on pigment was discovered incidentally in patients taking it for other indications. It blocks the plasminogen-plasmin pathway in keratinocytes, reducing the release of arachidonic acid and prostaglandins that stimulate melanocytes after ultraviolet exposure. It also appears to reduce the vascular component of melasma — the dilated dermal vessels that make lesions look darker and more persistent.

That second point matters. Melasma is not purely a pigment disorder; increased dermal vascularity is a recognised feature, which is one reason purely tyrosinase-directed treatments so often produce incomplete results. Tranexamic acid is used orally, topically and by intradermal microinjection, with the oral route having the largest supporting evidence base.

Why the Comparison Is Not Head-to-Head in Practice

Most consumer guides frame this as a contest with a winner. Clinically it rarely functions that way. Several randomised comparisons have found oral tranexamic acid combined with topical treatment to outperform topical treatment alone, and some have found tranexamic acid broadly comparable to hydroquinone on melasma severity scores. But the two agents are typically deployed at different stages: hydroquinone for a defined clearing phase, tranexamic acid for maintenance and for the vascular and recurrence-prone components.

The clinically meaningful question is therefore not which is superior, but which phase of a multi-year condition you are currently in. Melasma is chronic and relapsing. Treatments that clear it do not cure it, and any programme without a maintenance plan will disappoint.

Safety Limits That Genuinely Matter

Exogenous Ochronosis with Hydroquinone

Prolonged, unsupervised hydroquinone use — particularly at high concentrations over many months — has been associated with exogenous ochronosis, a paradoxical blue-grey darkening that is difficult to reverse. Risk appears higher in darker skin phototypes. This is the principal reason hydroquinone is prescribed in cycles, commonly 3 to 6 months with a break, rather than continuously. Irritant contact dermatitis and post-inflammatory hyperpigmentation are the other common adverse effects, and the latter can worsen the very problem being treated.

Thrombotic Risk with Oral Tranexamic Acid

Because tranexamic acid is antifibrinolytic, it is contraindicated in patients with a personal or family history of thromboembolism, active clotting disorders, and generally in those using combined hormonal contraception or with other significant thrombotic risk factors. Reported thrombotic events at the low doses used for melasma are rare, but screening is not optional. Any clinic offering oral tranexamic acid without taking a clotting and medication history is cutting a corner that matters.

Regulatory Status Varies by Country

Availability differs markedly between jurisdictions. Some countries restrict over-the-counter hydroquinone entirely; others permit low concentrations. Oral tranexamic acid for melasma is generally an off-label use of an approved drug. Verify the legal and prescribing status in both Korea and your home country before starting a course you will need to continue after you travel.

Sun Protection Is Not an Optional Add-On

Neither agent performs adequately without rigorous photoprotection, and visible light as well as ultraviolet radiation contributes to melasma in pigmented skin. Broad-spectrum sunscreen with iron oxides, which absorb visible light, is commonly recommended for this reason, alongside hats and shade-seeking behaviour. Studies of melasma relapse consistently identify inadequate sun protection as a leading driver. Treating melasma without addressing exposure is a reliable way to spend money for a temporary result.

How Korean Clinics Typically Sequence Treatment

A common structure runs roughly as follows. An initial clearing phase uses topical hydroquinone or a triple-combination cream for around 12 weeks, paired with strict photoprotection. Oral tranexamic acid may be added during or after this phase, subject to screening. Adjunctive procedures such as low-fluence laser toning or chemical peels are used cautiously, since aggressive energy-based treatment can aggravate melasma rather than improve it. A maintenance phase then relies on non-hydroquinone topicals, continued photoprotection, and where appropriate, ongoing tranexamic acid.

Energy-based devices deserve particular caution in melasma. Mechanism and settings determine whether a device helps or provokes rebound pigmentation, a distinction explored in our guide to how pico laser actually works.

Frequently Asked Questions

Can I use tranexamic acid and hydroquinone together?

Combination protocols are used in practice and several studies have examined them. Whether it is appropriate for you depends on your medical history, current medications and the severity of your melasma, and it should be a prescriber's decision rather than a self-directed one.

How long before I see results?

Most published courses report visible change at around 8 to 12 weeks for either agent, with continued improvement over subsequent months. Anyone promising clearance in a few weeks is describing marketing rather than pharmacology.

Will melasma come back if I stop?

Recurrence is common, particularly with sun exposure, pregnancy or hormonal changes. Melasma is best understood as a chronic condition managed over years, not an event that is cured once.

Is topical tranexamic acid as effective as oral?

The evidence base for the topical route is smaller and results have been more variable, largely because penetration is limited. It is a reasonable option for patients who cannot take the oral form, but it should not be presented as equivalent.

Does melasma treatment differ in darker skin types?

Yes, materially. Higher Fitzpatrick phototypes carry greater risk of post-inflammatory hyperpigmentation and exogenous ochronosis, which argues for gentler concentrations, shorter hydroquinone cycles and conservative device settings. Ask what phototype the clinic has recorded for you and how it changed their plan.

What to Ask Before Starting

Request a written protocol that states the concentration, the intended duration, the planned stopping point, the maintenance strategy after clearing, and the screening performed before any oral prescription. A melasma plan without a defined end date for hydroquinone and a defined maintenance phase is incomplete.

Sources and Further Reading

Background and verification: Korea Health Industry Development Institute (KHIDI) | Korean Medical Association (KMA) | PubMed: tranexamic acid and hydroquinone in melasma

This article is general information, not medical advice. Both agents require professional assessment, and oral tranexamic acid in particular requires screening for thrombotic risk before use.